The Uromigos

Episode 86: Career Development in Academic Oncology Part 1 - Moshe Ornstein 26.02.2021 20:55 ↓

In these podcasts, we explore academic career development with individuals in different stages of their career. 

Episode 85: The CLEAR Trial 14.02.2021 29:42 ↓

Toni Choueiri discusses the phase three results

Episode 84: Prostate cancer highlights from ASCO #GU21 with Chris Sweeney 13.02.2021 17:24 ↓

Chris explores the prostate cancer programme. 

Episode 82: Which is the best VEGF/immune combination for first line metastatic renal cancer? 13.02.2021 24:40 ↓

Eric Jonash gives a thoughtful answer to this issue. 

Episode 83: Is cabozantinib the new standard of care in papillary renal cancer? 13.02.2021 21:54 ↓

Monty Pal discusses his randomised phase 2 study in papillary renal cancer. 

Episode 81: Noah Hahn discusses front line cisplatin-ineligible PD-L1 data from 361 and 130 13.02.2021 21:22 ↓

These new data are important as it is the setting where these agents are currently recommended, but we have not seen the data in this specific subset until now. 

Episode 80: Results for Darolutamide in non-metastatic CRPC - the Aramis trial 13.02.2021 19:52 ↓

Neil Shore presents the impressive updates for the results of this trial. 

Episode 79: Adjuvant nivolumab in operable urothelial cancer 13.02.2021 24:36 ↓

Matt Galski discusses this potentially practice-changing study. 

Episode 78: Enfortumab Vedotin Special: EV301 randomised trial and EV201 in urothelial cancer 12.02.2021 22:39 ↓

Arjun Balar discusses these studies and the impact they will have. 

Episode 77: The Uromigos Paper of the Month - Nadofaragene for BCG unresponsive NMIBC 06.02.2021 17:21 ↓

Stephen Boorjian outlines his recent Lancet oncology paper. Tom and Brian struggle to keep up. 

Episode 76: Tom Hutson discusses lenvatinib and everolimus 22.01.2021 23:51 ↓

Discussion on lenvatinib and everolimus prior to the CLEAR trial presentation. 

Episode 75: The Uromigos meet APCCC - bone health and bone disease in prostate cancer with Bertrand Tombal 14.01.2021 25:47 ↓

Silke, Chris and Bertrand discuss bone protective therapy and bone targeted therapy. 

Episode 74: The Uromigos meet APCCC Round 2: First line treatment - low vs high volume; chemo vs abi/enza 11.01.2021 32:05 ↓

Nick James and Chris Sweeney debate this issue. Tom and Silke try to keep things on track. 

Episode 73: The Uromigos meet APCCC in a discussion on oligometastatic prostate cancer @APCCC_Lugano 08.01.2021 25:11 ↓

Piet Ost, Chris Sweeney and Silke Gillessen discuss controversies around the management of oligometastatic prostate cancer. 

Episode 72: Uromigos Christmas Special - Renal cancer year in review 21.12.2020 24:25 ↓

Laurence Albiges discusses renal cancer highlights from the year. 

Episode 71: Bladder Cancer Uromigos Christmas Special with Matt Galsky 18.12.2020 24:57 ↓

Matt discusses the year in review, including first line and adjuvant immune therapy studies, ADCs and FGFR targeting are also discussed. 

Episode 70: The Uromigos Prostate Cancer Christmas Special with Chuck Ryan 11.12.2020 25:56 ↓

A review of the year in prostate cancer with Chuck Ryan. 

Episode 69: Testis Cancer Christmas Special: 2020 year in review 09.12.2020 25:16 ↓

Christian Kollmannsberger gets into the Christmas spirit by discussing highlights of 2020. 

Episode 68: Uromigos Paper of the Month - a molecular classification of renal cancer in Cancer Cell 08.12.2020 26:24 ↓

Kim Rathmell discusses this paper, which divides clear cell renal cancer into seven relevant subgroups. Brian askes an interesting question at one point. 

Episode 67: The Third Uromigos Debate - PD1/VEGF vs PD1/CTLA4 for front line renal cancer 17.11.2020 28:48 ↓

David McDermott and Brian Rini debate treatment options in front line renal cancer. It's hard to identify any winners from this podcast.

Episode 66: Uromigos Paper of the Month - Two papers in Nature Medicine on neoadjuvant immune combinations in bladder cancer 09.11.2020 30:49 ↓

Pam Sharma and Michiel Van Der Heijden discuss neoadjuvant PD(L)1 + CTLA4 inhibition in urothelial cancer. 

Episode 65: Review of the International Kidney Cancer Symposium 02.11.2020 22:31 ↓

Gretchen Vaughan, Kidney Cancer Association CEO, discusses the upcoming International Kidney Cancer Symposium meeting and KCA's grant program. Tom and Brian review some of the top abstracts. 

Episode 64: The Second Uromigos debate with Nobel Laureate Bill Kaelin on new biomarker vs new drugs in RCC 28.10.2020 28:57 ↓

'New Drugs vs New Biomarkers' Bill Kaelin (Nobel Laureate) vs Tom Powles (keen cyclist), extend their discussion from KCRS20 in the 2nd Uromigos Debate. 

Episode 63: The First Uromigos Debate: front line immune therapy vs maintenance avelumab in bladder cancer 09.10.2020 21:19 ↓

Dr. Peter O'Donnell and Prof. Tom Powles debate front line treatment options in urothelial cancer. 

Episode 62: James Eastham's Uromigos Paper of the Month - Prostatectomy +/- Neoadjuvant Chemo 06.10.2020 27:44 ↓

A large randomised investigator-initiated Alliance study gives insight in to perioperative treatments for high risk prostate cancer.